指南与共识细菌感染、耐药与抗菌药物医院感染防控

欧洲临床微生物学和感染病学会/欧洲感染控制委员会临床指南:多重耐药革兰阳性菌定植患者术前去定植与靶向预防

European Society of Clinical Microbiology and Infectious Diseases/European Committee on infection control clinical guidelines on pre-operative decolonization and targeted prophylaxis in patients colonized by multidrug-resistant Gram-positive bacteria before surgery.
指南 / 共识 · Clin Microbiol Infect · 2024-08-21

该指南由欧洲临床微生物学和感染病学会/欧洲感染控制委员会制定,系统综述截至2023年11月1日的文献,针对耐甲氧西林金黄色葡萄球菌(MRSA)、耐万古霉素肠球菌、耐甲氧西林凝固酶阴性葡萄球菌及泛耐药革兰阳性菌定植的成人手术患者,给出围手术期去定植和靶向抗生素预防的建议,涵盖筛查、去定植、靶向预防及联合干预,并纳入抗菌药物管理考量。

要点

  • 推荐在高风险手术(如心胸外科和骨科手术)前筛查金黄色葡萄球菌。
  • 金黄色葡萄球菌定植患者在心胸外科和骨科手术前推荐鼻内莫匹罗星去定植,联用或不联用氯己定沐浴;其他手术建议(弱推荐)使用。
  • MRSA定植者接受心胸外科、骨科或神经外科手术时,建议(弱推荐)在标准预防基础上加用万古霉素。

核心结论

  • 指南针对多重耐药革兰阳性菌定植的成人手术患者,提出了去定植和靶向围手术期抗生素预防的建议,但耐万古霉素肠球菌因缺乏数据未给出建议,耐甲氧西林凝固酶阴性葡萄球菌和泛耐药革兰阳性菌未检索到证据。

研究设计与样本

  • 欧洲临床微生物学和感染病学会/欧洲感染控制委员会遵循系统综述制定指南,证据等级和推荐强度采用推荐分级的评估、制定与评价(GRADE)方法,由多学科专家组达成共识,最终检索日期为2023年11月1日。

主要发现

  • 关键结局为定植多重耐药革兰阳性菌引起的手术部位感染(SSI)发生率和SSI归因死亡率;重要结局包括任何病原体引起的SSI、医院获得性感染、全因死亡率及干预相关不良事件(包括所用药物耐药发展和艰难梭菌感染发生率)。
  • 指南专家组按细菌类型和手术类型审查了去定植、靶向围手术期抗生素预防及联合干预(如去定植联合靶向预防)对多重耐药革兰阳性菌定植者SSI风险和其他结局的影响。

关键数值与推荐

  • 推荐在高风险手术(如心胸外科和骨科手术)前筛查金黄色葡萄球菌。
  • 金黄色葡萄球菌定植患者在心胸外科和骨科手术前推荐鼻内莫匹罗星去定植,联用或不联用氯己定沐浴;其他手术建议(弱推荐)使用。
  • MRSA定植者接受心胸外科手术、骨科手术和神经外科手术时,建议(弱推荐)在标准预防基础上加用万古霉素。
  • MRSA定植者接受心胸外科和骨科手术时,建议(弱推荐)联合干预(如去定植和靶向预防)。
  • 耐万古霉素肠球菌因缺乏数据,无法就筛查、去定植和靶向预防给出建议;耐甲氧西林凝固酶阴性葡萄球菌和泛耐药革兰阳性菌未检索到证据。

临床怎么用

  • 实施筛查程序或更改围手术期抗生素预防政策前,应仔细考虑实验室工作量,并需抗菌药物管理和感染控制团队参与。
  • 未来研究应聚焦新型去定植技术、去定植药物和围手术期抗生素预防方案的耐药监测,以及高质量研究中的标准化联合干预。

局限性

  • 耐万古霉素肠球菌因缺乏数据,无法就筛查、去定植和靶向预防给出建议。
  • 耐甲氧西林凝固酶阴性葡萄球菌和泛耐药革兰阳性菌未检索到证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SCOPE: The aim of these guidelines is to provide recommendations for decolonization and perioperative antibiotic prophylaxis (PAP) in multidrug-resistant Gram-positive bacteria (MDR-GPB) adult carriers before inpatient surgery. METHODS: These European Society of Clinical Microbiology and Infectious Diseases/European Committee on Infection Control guidelines were developed following a systematic review of published studies targeting methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci, methicillin-resistant coagulase-negative Staphylococci, and pan-drug-resistant-GPB. Critical outcomes were the occurrence of surgical site infections (SSIs) caused by the colonizing MDR-GPB and SSIs-attributable mortality. Important outcomes included the occurrence of SSIs caused by any pathogen, hospital-acquired infections, all-cause mortality, and adverse events associated with the interventions, including resistance development to the agents used and the incidence of Clostridioides difficile infections. The last search of all databases was performed on 1 November 2023. The level of evidence and the strength of each recommendation were defined according to the Grading of Recommendations Assessment, Development, and Evaluation approach. Consensus of a multidisciplinary expert panel was reached for the final list of recommendations. Antimicrobial stewardship considerations were included. RECOMMENDATIONS: The guideline panel reviewed the impact of decolonization, targeted PAP, and combined interventions (e.g. decolonization and targeted PAP) on the risk of SSIs and other outcomes in MDR-GPB carriers, according to the type of bacteria and type of surgery. We recommend screening for S. aureus before high-risk operations, such as cardiothoracic and orthopaedic surgery. Decolonization with intranasal mupirocin with or without a chlorhexidine bath is recommended in patients colonized with S. aureus before cardiothoracic and orthopaedic surgery and suggested in other surgeries. The addition of vancomycin to standard prophylaxis is suggested for MRSA carriers in cardiothoracic surgery, orthopaedic surgery, and neurosurgery. Combined interventions (e.g. decolonization and targeted prophylaxis) are suggested for MRSA carriers undergoing cardiothoracic and orthopaedic surgery. No recommendation could be made regarding screening, decolonization and targeted prophylaxis for vancomycin-resistant enterococci because of the lack of data. No evidence was retrieved for methicillin-resistant coagulase-negative Staphylococci and pan-drug-resistant-GPB. Careful consideration of the laboratory workload and involvement of antimicrobial stewardship and infection control teams are warranted before implementing screening procedures or performing changes in PAP policy. Future research should focus on novel decolonizing techniques, on the monitoring of resistance to decolonizing agents and PAP regimens, and on standardized combined interventions in high-quality studies.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Righi E, Mutters NT, Guirao X, et al. European Society of Clinical Microbiology and Infectious Diseases/European Committee on infection control clinical guidelines on pre-operative decolonization and targeted prophylaxis in patients colonized by multidrug-resistant Gram-positive bacteria before surgery. Clin Microbiol Infect. 2024. PMID: 39154859. doi:10.1016/j.cmi.2024.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。